Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “High Risk Newly Diagnosed Multiple Myeloma”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Study completedNCT01255514
What this trial is testing

Sequential High-dose Dexamethasone and Response Adopted PAD or VAD Induction Chemotherapy Followed by High-dose Chemotherapy With Autologous Stem Cell Transplantation for Newly Diagnosed Multiple Myeloma

Who this might be right for
Multiple Myeloma
Yonsei University 30
Testing effectiveness (Phase 2)UnknownNCT00702247
What this trial is testing

Tandem Autologous- Nonmyeloablative Allogeneic Transplant for Newly Diagnosed Multiple Myeloma (Trapianto Tandem Autologo-Allogenico Non Mieloablativo Nel Mieloma Alla Diagnosi)

Who this might be right for
Multiple Myeloma
Azienda Ospedaliera San Giovanni Battista
Early research (Phase 1)Study completedNCT04196491
What this trial is testing

Evaluate the Safety of bb2121 in Subjects With High Risk, Newly Diagnosed Multiple Myeloma (NDMM)

Who this might be right for
Multiple Myeloma
Celgene 13
Testing effectiveness (Phase 2)Study completedNCT00691704
What this trial is testing

Celgene High Risk Multiple Myeloma (MM) Revlimid Induction and Maintenance Therapy

Who this might be right for
Multiple Myeloma
Cristina Gasparetto 18
Large-scale testing (Phase 3)Study completedNCT01208766
What this trial is testing

Study to Compare VMP With HDM Followed by VRD Consolidation and Lenalidomide Maintenance in Patients With Newly Diagnosed Multiple Myeloma

Who this might be right for
Multiple Myeloma
Stichting Hemato-Oncologie voor Volwassenen Nederland 1,503
Testing effectiveness (Phase 2)Looking for participantsNCT07106710
What this trial is testing

ASCT Combined With BCMA CAR-T and GPRC5D/CD3 BiTEs Maintenance for Transplant-Eligible Ultra-High-Risk Multiple Myeloma

Who this might be right for
Multiple Myeloma, Newly Diagnosed
Institute of Hematology & Blood Diseases Hospital, China 30
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07029776
What this trial is testing

MMulti-Immune HR; Multi-Target Immunotherapy for High-Risk Multiple Myeloma

Who this might be right for
Multiple Myeloma (MM)
University of Arkansas 50
Early research (Phase 1)Not Yet RecruitingNCT05181501
What this trial is testing

Fully Human BCMA CAR-T (CT103A) in Patients With Newly Diagnosed High-risk Multiple Myeloma (FUMANBA-2)

Who this might be right for
Multiple Myeloma
Nanjing IASO Biotechnology Co., Ltd. 20
Large-scale testing (Phase 3)Active Not RecruitingNCT00602641
What this trial is testing

Melphalan, Prednisone, and Thalidomide or Lenalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma

Who this might be right for
Multiple Myeloma
National Cancer Institute (NCI) 306
Large-scale testing (Phase 3)Study completedNCT03993912
What this trial is testing

Compare Lenalidomide and Subcutaneous Daratumumab vs Lenalidomide and Dexamethasone in Frail Subjects With Previously Untreated Multiple Myeloma Who Are Ineligible for High Dose Therapy

Who this might be right for
Multiple Myeloma
University Hospital, Lille 294
Large-scale testing (Phase 3)WithdrawnNCT07428369
What this trial is testing

Linvo-VR vs DVRd in Transplant-Eligible Adult Participants With Newly Diagnosed Multiple Myeloma (NDMM)

Who this might be right for
Multiple Myeloma (MM)
Regeneron Pharmaceuticals
Testing effectiveness (Phase 2)Ended earlyNCT02573935
What this trial is testing

Clarithromycin in Multiple Myeloma Induction Therapy

Who this might be right for
Multiple Myeloma
Henrik Gregersen 58
Large-scale testing (Phase 3)Study completedNCT00205764
What this trial is testing

Tandem High Dose Melphalan Versus Triple Intermediate Dose Melphalan and Stem Cell Transplantation in Induction Phase and Prednisolone/IFN Versus IFN in Maintenance Therapy

Who this might be right for
Multiple Myeloma
Austrian Forum Against Cancer 212
Testing effectiveness (Phase 2)WithdrawnNCT03785184
What this trial is testing

Venetoclax Plus Lenalidomide and Dexamethasone for the Treatment of Newly Diagnosed t(11;14)-Positive Multiple Myeloma in Subjects Who Are Ineligible for High-Dose Therapy

Who this might be right for
Multiple Myeloma
AbbVie
Testing effectiveness (Phase 2)Study completedNCT02217163
What this trial is testing

Carfilzomib, Cyclophosphamide, Dexamethasone in Transplant Eligible Newly Diagnosed High-risk Multiple Myeloma

Who this might be right for
Multiple Myeloma
Singapore General Hospital 30
Large-scale testing (Phase 3)Looking for participantsNCT05665140
What this trial is testing

Expression-linked and R-ISS-adapted Stratification for First Line Therapy in Multiple Myeloma Patients

Who this might be right for
Newly Diagnosed Multiple Myeloma
University Hopsital Schleswig Holstein Campus Lübeck 100
Testing effectiveness (Phase 2)UnknownNCT05422027
What this trial is testing

Selinexor Plus VRd in High Risk Newly Diagnosed Multiple Myeloma

Who this might be right for
Multiple Myeloma
Xia Zhongjun 42
Testing effectiveness (Phase 2)Ended earlyNCT00337506
What this trial is testing

Velcade Combined With High-Dose Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma

Who this might be right for
Multiple Myeloma
Nantes University Hospital 50
Post-approval studies (Phase 4)Looking for participantsNCT06409702
What this trial is testing

Treatment of High-risk Newly Diagnosed Multiple Myeloma With Minimal Residual Disease Detection

Who this might be right for
Newly DiagnosedHigh RiskMRD+1 more
The First Affiliated Hospital of Soochow University 59
Testing effectiveness (Phase 2)Study completedNCT02937571
What this trial is testing

High Dose Carfilzomib for Newly Diagnosed Myeloma

Who this might be right for
Multiple Myeloma
Memorial Sloan Kettering Cancer Center 29
Next Page